Beta-Adrenergic Blockers

Core Concepts

The receptors: beta-1 and beta-2

The sympathetic nervous system ("fight or flight") releases norepinephrine and epinephrine, which bind to beta-adrenergic receptors — two types matter most here:

• Beta-1 receptors are concentrated in the heart: stimulation increases heart rate (chronotropy), force of contraction (inotropy), and conduction speed (dromotropy), and triggers renin release, which kicks off the RAAS.
• Beta-2 receptors are found in the airways (bronchial smooth muscle), skeletal-muscle blood vessels, the liver, and the uterus: stimulation relaxes those tissues (bronchodilation, vasodilation, glycogen release).

What beta-blockers do

By occupying beta receptors, beta-blockers prevent epinephrine and norepinephrine from acting:

• Heart: lower heart rate, weaker contraction, slower conduction → lower cardiac output and less myocardial oxygen demand — the antianginal effect (the heart needs less oxygen, so a fixed coronary supply lasts longer).
• Blood pressure: lower cardiac output plus reduced renin release → lower blood pressure over time.
• Kidney: less renin → less angiotensin II and aldosterone downstream → less vasoconstriction and volume retention.
• Dysrhythmias: slowing the sinus and AV nodes helps rate control in atrial fibrillation and suppresses certain tachyarrhythmias.

Cardioselective vs. nonselective — why it matters

• Cardioselective (beta-1 selective): metoprolol, atenolol, bisoprolol, esmolol, nebivolol. At usual doses they spare beta-2 receptors, so they are relatively safer in people with asthma or COPD. Selectivity is dose-dependent: at high doses, "selective" drugs start blocking beta-2 too.
• Nonselective: propranolol, nadolol, timolol, pindolol, sotalol. They block both beta-1 and beta-2. In a person with reactive airway disease, blocking beta-2 can trigger bronchospasm — the classic reason nonselective beta-blockers are avoided or used with great caution in asthma.
• Alpha + beta blockers: carvedilol and labetalol also block alpha-1 receptors, which dilates blood vessels and lowers blood pressure further. Carvedilol, bisoprolol, and metoprolol succinate are among the beta-blockers studied in heart failure with reduced ejection fraction.

Uses in this chapter's context

• Hypertension: beta-blockers lower blood pressure; they are one of several first-line-capable classes depending on the person's other conditions.
• Angina: by reducing heart rate and contractility, they cut myocardial oxygen demand, so chest pain occurs less often with exertion.
• Post-myocardial infarction: long-term beta-blockade reduces the risk of another event and sudden death in many people with coronary disease.
• Heart failure (reduced ejection fraction): in carefully selected, stable people, certain beta-blockers (carvedilol, bisoprolol, metoprolol succinate) improve survival; starting them can transiently worsen symptoms, so initiation is slow and monitored per the prescriber's plan.
• Rate control: in atrial fibrillation, beta-blockers slow ventricular response.

Adverse effects and nursing vigilance

• Bradycardia and AV block: the heart slows; if too slow, people feel dizzy, tired, or short of breath. Nurses check heart rate and blood pressure before administration per orders.
• Bronchospasm: mainly with nonselective agents in people with reactive airway disease — wheezing, dyspnea.
• Masked hypoglycemia: blunted tachycardia means a person with diabetes may not feel the usual "racing heart" warning of low blood sugar; sweating and tremor may still occur. Teach blood glucose monitoring and symptom recognition per the care plan.
• Fatigue, cold hands/feet, depression, sexual dysfunction: common and under-reported; asking directly helps people stay on therapy.
• Worsening heart failure: in unstable heart failure, removing sympathetic support can unmask decompensation — why initiation is slow and monitored.
• Abrupt withdrawal: rebound sympathetic overactivity (tachycardia, hypertension, angina, arrhythmias); beta-blockers are tapered, never stopped abruptly — prescriber-directed.

Person-first, scope-aware care

Talk about "a person with angina who takes metoprolol," not "a beta-blocker patient." Heart-rate thresholds, titration schedules, and who may initiate therapy vary by guideline, state nurse practice act, and institutional policy. Educational content describes the class; actual doses, schedules, hold parameters, and decisions must always be verified against current references, the facility formulary, and the prescriber's orders.

Common Confusions